Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

Davidson D, Wang Y, Aloyz R, Panasci L.

Invest New Drugs. 2013 Apr;31(2):461-8. doi: 10.1007/s10637-012-9886-7. Epub 2012 Oct 9.


Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.


Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Clark CC, Weitzel JN, O'Connor TR.

Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.


Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B.

Mol Cancer Ther. 2003 Apr;2(4):371-82.


Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.


Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.

Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, Zhu GD, Penning T, Rosenberg S, Giranda VL, Luo Y, Leverson J, Johnson EF, Shoemaker AR.

Mol Cancer Res. 2009 Oct;7(10):1686-92. doi: 10.1158/1541-7786.MCR-09-0299. Epub 2009 Oct 13.


Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.

Muñoz-Gámez JA, López Viota J, Barrientos A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P, Delgado Á, Ruiz-Extremera Á, Salmerón J.

Liver Int. 2015 Apr;35(4):1430-41. doi: 10.1111/liv.12586. Epub 2014 Jun 3.


Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.

Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P.

Anticancer Drugs. 2001 Oct;12(9):741-51.


Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.

Tentori L, Leonetti C, Muzi A, Dorio AS, Porru M, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.

Int J Oncol. 2013 Jul;43(1):210-8. doi: 10.3892/ijo.2013.1932. Epub 2013 May 8.


Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.

Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio AS, Zhang J, Cuzzocrea S, Graziani G.

FASEB J. 2006 Aug;20(10):1709-11. Epub 2006 Jun 29.


Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.

Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL.

Breast Cancer Res Treat. 2012 Jul;134(2):649-59. doi: 10.1007/s10549-012-2106-5. Epub 2012 Jun 8.


The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.

Somnay Y, Lubner S, Gill H, Matsumura JB, Chen H.

Cancer Gene Ther. 2016 Oct;23(10):348-354. doi: 10.1038/cgt.2016.39. Epub 2016 Sep 16.


ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.

Siddharth S, Nayak D, Nayak A, Das S, Kundu CN.

DNA Repair (Amst). 2016 Sep;45:44-55. doi: 10.1016/j.dnarep.2016.05.034. Epub 2016 Jun 3.


Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.

Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H.

Breast Cancer. 2014 Jan;21(1):75-85. doi: 10.1007/s12282-012-0356-z. Epub 2012 Mar 28.


The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.

Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R, Zulli A, Parchment R, Ruggeri B.

Mol Cancer Ther. 2007 Aug;6(8):2290-302.


In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.

Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, El-Rayes B, Shu HK.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):469-76. doi: 10.1016/j.ijrobp.2013.02.015. Epub 2013 Mar 26.


Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ, Kirkby NF.

Radiat Oncol. 2013 Mar 19;8:65. doi: 10.1186/1748-717X-8-65.


Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodkinson K, Masson JY, Aloyz R, Panasci L.

Invest New Drugs. 2012 Jun;30(3):1248-56. doi: 10.1007/s10637-010-9626-9. Epub 2011 Jan 11.


Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.

Zhou Q, Ji M, Zhou J, Jin J, Xue N, Chen J, Xu B, Chen X.

Biochem Pharmacol. 2016 May 1;107:29-40. doi: 10.1016/j.bcp.2016.02.015. Epub 2016 Feb 24.


Supplemental Content

Support Center